Adherence measured by Medication event monitoring system in TPiple Antihypertensive Combination: single- versus two-pill regimen

Sungkyunkwan University School of Medicine0 个研究点目标入组 145 人开始时间: 2016年3月3日最近更新: 2023年5月8日

适应症

试验速览

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33503302/ (added 25/04/2023)

•1. Hypertensive patients whose clinic BP (defined below) is systolic > 140 mmHg or diastolic > 90 mmHg, and has been on dual-component therapy for at least 4 weeks with one of the following combination either in SPC or free-equivalent combination in a dose equivalent dose to olmesartan 20 mg or amlodipine 5 mg or hydrochlorothiazide 12.5 mg/day:
•1.1. Angiotensin receptor blocker(ARB) + Calcium channel blocker(CCB)
•1.2. ARB + thiazide diuretics
•1.3. CCB + thiazide diuretics
•2. Patients who provide informed consent to join the study
•3. Aged 18 years or over

•1. Severe HTN (baseline clinic SBP > 180 mmHg or DBP > 110 mmHg)
•2. Suspicious of secondary HTN or any other severe target organ damage or hypertensive emergency necessitating urgent BP control
•3. Past history of intolerance or existing contraindication to either CCB or ARB or thiazide diuretics
•4. Medical conditions which are likely to result in regimen change such as recent (within 6 months) major cardiovascular events.
•5. Cases with severe comorbidities which is considered to be inappropriate for enrollment by investigators, including (but not confined to) severe hepatic or renal insufficiency, dementia with significant problem in keeping regular medication, etc.
•6. Pregnancy or planned pregnancy

发起方

Sungkyunkwan University School of Medicine